James Kaufman

Agricultural Economist


James Kaufman is an agricultural economist in the International Trade and Development (ITD) branch of the Market and Trade Economics Division at the USDA’s Economic Research Service (ERS).


James Kaufman joined the ERS in 2021. Prior to joining the ERS, James spent 21 years at the University of Missouri, where he was a project director in the Division of Applied Social Sciences. Much of his work focused on researching the economics and policy of biotechnology, and other agrifood innovations. His work specifically focused on the economic impacts of biotechnology, the impacts of innovation on the structure of the global agrifood supply chain, the interactions of agrifood innovation and international trade, and on the regulation of biotechnology.


James received an M.S. in Agricultural Economics at the University of Missouri and a B.S. in Agricultural Business at Truman State University.

Selected Publications

Kalaitzandonakes, N., J. Kaufman, and K. Zahringer. 2019. The Economics of Soybean Disease Control, CABI.

Kalaitzandonakes, N., J. Kaufman, S. Yea, and K. Zahringer. 2016. “Potential Economic Impacts of Asynchronous Approvals of Biotech Crops on South Korea,” In The Coexistence of Genetically Modified, Organic and Conventional Foods (pages 257-282). Springer, New York, NY.

Kalaitzandonakes, N., J. Kaufman, and D. Miller. 2014. “Potential Economic Impacts of Zero Thresholds for Unapproved GMOs: The EU Case,” Food Policy 45:146-157.

Kalaitzandonakes, N., J. Kaufman, and D. Miller. 2014. “Economic Impact Analysis of Potential Trade Restrictions on Biotech Maize in Latin American Countries,” In Modeling, Dynamics, Optimization and Bioeconomics I. A. Pinto and D. Zilberman, eds. pages 383-404. Springer.

Kaufman, J. and N. Kalaitzandonakes. 2011. “Mitigating Environmental Externalities in Livestock Production Through Feed Biotechnologies,” Agricultural Systems 104:770-780.

Kaufman, J. and N. Kalaitzandonakes. 2011. “The Economic Potential of Plant-Made Pharmaceuticals in the Manufacture of Biologic Pharmaceuticals,” Journal of Commercial Biotechnology 17:173-182.